Enzon Pharmaceuticals (ENZN) Receiving Somewhat Critical Press Coverage, Analysis Finds
News articles about Enzon Pharmaceuticals (NASDAQ:ENZN) have trended somewhat negative on Monday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enzon Pharmaceuticals earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.3322506290571 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Enzon Pharmaceuticals (NASDAQ:ENZN) traded up 0.854% during trading on Monday, hitting $0.242. 260,088 shares of the stock traded hands. The firm has a market capitalization of $10.70 million and a price-to-earnings ratio of 12.100. Enzon Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $0.50. The firm has a 50-day moving average of $0.38 and a 200-day moving average of $0.31.
The company also recently announced a dividend, which was paid on Thursday, September 28th. Investors of record on Wednesday, August 30th were paid a dividend of $0.15 per share. The ex-dividend date was Friday, September 29th.
About Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C.
Receive News & Ratings for Enzon Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.